A Phase 1b/2 Dose-Escalation and Cohort-Expansion Study of the Noncovalent, Reversible Bruton's Tyrosine Kinase Inhibitor, SNS-062, in Patients With B-Lymphoid Malignancies

Trial Profile

A Phase 1b/2 Dose-Escalation and Cohort-Expansion Study of the Noncovalent, Reversible Bruton's Tyrosine Kinase Inhibitor, SNS-062, in Patients With B-Lymphoid Malignancies

Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 05 Dec 2017

At a glance

  • Drugs Vecabrutinib (Primary)
  • Indications Chronic lymphocytic leukaemia; Haematological malignancies; Mantle-cell lymphoma; Waldenstrom's macroglobulinaemia
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors Sunesis Pharmaceuticals
  • Most Recent Events

    • 05 Dec 2017 According to a Sunesis Pharmaceuticals media release, company will provide an update of the clinical trial at the 59th American Society of Hematology (ASH) Annual Meeting in 2017.
    • 02 Nov 2017 According to a Sunesis Pharmaceuticals media release, the company expects to present interim data from the study at a peer-reviewed medical conference in mid-2018.
    • 18 Jul 2017 According to a Sunesis Pharmaceuticals media release, the first patient has been dosed in this trial.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top